BALTIMORE--(BUSINESS WIRE)--The Global Virus Network (GVN), a coalition of the world’s leading medical virology research centers working together to prevent illness and death from viral disease, today announced the election of finance and business leader N. Scott Fine as Chairman of the Board of Directors. Mr. Fine succeeds the outgoing Board Chairman, attorney Timothy C. Moynahan, who will take on a new role as Board Vice Chairman. The announcement was made by Robert C. Gallo, MD, GVN Co-Founder and Director of GVN’s Center of Excellence at the Institute of Human Virology at the University of Maryland School of Medicine; William Hall, MD, PhD, GVN Co-Founder and Director of the GVN’s Center of Excellence at the University College Dublin; and GVN President Sharon Hrynkow, PhD.
“Mr. Fine brings not only exceptional business skills and acumen to GVN but an undeniable passion for improving the health of humanity,” said Dr. Gallo. “We are delighted to be able to call him colleague, partner and Chairman.”
“I am honored to have been elected by the Board of GVN as its Chairman, and I look forward to working with Dr. Gallo, Dr. Hrynkow, and the full Board, to continue to build the GVN on the platform so well established through Tim Moynahan's leadership,” said Mr. Fine.
Mr. Fine has been involved in Investment Banking for over 35 years, working on a multitude of debt and equity financings, buy and sell side M&A, strategic advisory work and corporate restructurings. He has worked with a number of companies in the healthcare, biotechnology and medical device sectors. Mr. Fine advised Research Medical, a specialty medical device manufacturer, on a strategic equity alliance with The Tempo Group of Jakarta, Indonesia. Research Medical was subsequently acquired by Baxter. Mr. Fine also was the lead investment banker on the Initial Public Offering for Med-Design Corporation, a specialty medical device company, which was later acquired by Specialized Health Products International, Inc. Last year, Mr. Fine was appointed Chairman of the Board of Directors of CTD Holdings, Inc. (OTCQB: CTDH), a biotechnology company with an orphan drug designation for the treatment of Niemann-Pick Type C, a rare and fatal disease in children.
“This is a critical moment in global health, as the Ebola crisis has taught us all so painfully. As GVN works to build bridges between the academic community and private sector to create life-saving drugs and treatments for all viral diseases, Mr. Fine brings knowledge and insights that we know will propel us forward in meeting our vital goals," said GVN President Dr. Sharon Hrynkow.
About the Global Virus Network (GVN)
The Global Virus Network (GVN) is a non-profit, 501(c)(3) organization, comprised of leading medical virologists from 25 countries, and growing. The GVN’s mission is to combat current viral threats and emerging pandemic threats through international collaborative research, training the next generation of medical virologists, and advocacy. For more information, please visit www.gvn.org. Follow us on Twitter @GlobalVirusNews